Natural Product (NP) Details

General Information of the NP (ID: NP7663)
Name
Cidofovir
Synonyms
Cidofovir; 113852-37-2; Vistide; HPMPC; Cidofovir anhydrous; (S)-HPMPC; Cidofovirum; GS-504; Cidofovir (Vistide); Cidofovir hydrate; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; CDV; UNII-768M1V522C; GS-0504; [1-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-propan-2-yl]oxymethylphosphonic acid; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine; (S)-(((1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl)oxy)methyl)phosphonic acid; CHEBI:3696; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 768M1V522C; NCGC00184994-01; 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; 1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine; Cidofovir (anhydrous); Cidofovir hydrate (1:2); Forvade; GS 0504; (S)-(3-(4-amino-2-oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid; [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid; Cidofovir [INN]; ({[(2S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; C8H14N3O6P; HSDB 7115; GS504; Cidofovir gel; Cidofovir,Vistide; Cidofovir(Vistide); Forvade (TM); Cidofovir(anhydrous); Cidofovir, anhydrous; (S)-HPMPC; Cidovir; CHEMBL152; SCHEMBL3948; DSSTox_CID_23734; DSSTox_RID_80069; DSSTox_GSID_43734; (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; cc-166; MLS003915629; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; DTXSID3043734; BDBM31915; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate; BCP03734; EBD21562; EX-A4209; ZINC1530600; Tox21_112994; CC0162; MFCD00866936; MFCD17215968; NSC742135; s1516; AKOS005145721; AKOS015854828; AC-1666; BCP9000528; CCG-267235; CS-1669; DB00369; GS-6438; NSC-742135; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; [(1S)-1-[(4-amino-2-oxo-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphonic acid; NCGC00184994-02; NCGC00184994-03; HY-17438; Phosphonic acid, ((2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (S)-; SMR002544687; BCP0726000147; CAS-113852-37-2; AB01566823_01; 394C661; Q423445; SR-01000931969; J-502695; SR-01000931969-2; [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; L8P; Phosphonic acid, [[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-; Phosphonic acid,[[(1S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Cytomegaloviral disease [ICD-11: 1D82] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C8H14N3O6P
PubChem CID
60613
Canonical SMILES
C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
InChI
1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
InChIKey
VWFCHDSQECPREK-LURJTMIESA-N
CAS Number
CAS 113852-37-2
ChEBI ID
CHEBI:3696
TTD Drug ID
D04AAW
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cetuximab      Colorectal cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Phosphorylation H2AFX  Molecule Info 
Pathway MAP
                    In-vitro Model HeLa CVCL_0030 Endocervical adenocarcinoma Homo sapiens
ME-180 CVCL_1401 Cervical squamous cell carcinoma Homo sapiens
C-33 A CVCL_1094 Cervical squamous cell carcinoma Homo sapiens
                    In-vivo Model For a xenograft model, cells (2*106 Me180, HeLa, or C33A) were injected subcutaneously into female nude mice aged 10-12weeks (Elevage Janvier).
                    Experimental
                    Result(s)		 Cidofovir and Cetuximab have synergistic antitumor effect in HPV-positive tumors.
          Idoxuridine      Herpes simplex infection     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Chick embryo fibroblasts infected with Bratislava and RIIPD strains Microorganism model Gallus gallus
                    Experimental
                    Result(s)		 The combined effect of CDV and IUdR on VV replication in monolayer CEF cultures was characterized as a markedly synergistic one.
Target and Pathway
Target(s) Herpes simplex virus DNA polymerase UL30 (HSV UL30)  Molecule Info  [4]
References
Reference 1 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
Reference 2 The combination of the antiviral agent cidofovir and anti-EGFR antibody cetuximab exerts an antiproliferative effect on HPV-positive cervical cancer cell lines' in-vitro and in-vivo xenografts. Anticancer Drugs. 2013 Jul;24(6):599-608.
Reference 3 Synergistic combination effect of cidofovir and idoxuridine on vaccinia virus replication. Antivir Chem Chemother. 2006;17(2):53-8.
Reference 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link